Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Net Cash Flow (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Net Cash Flow for 3 consecutive years, with $65.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 1331.49% to $65.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $128.6 million, a 1843.16% increase, with the full-year FY2025 number at $128.6 million, up 1843.16% from a year prior.
  • Net Cash Flow was $65.4 million for Q4 2025 at Nuvation Bio, up from -$149.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $200.1 million in Q2 2025 to a low of -$149.0 million in Q3 2025.
  • A 3-year average of $5.2 million and a median of $2.1 million in 2024 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 66139.27% in 2025; the steepest drop was 4149.22% in 2025.
  • Nuvation Bio's Net Cash Flow stood at $18.3 million in 2023, then tumbled by 74.96% to $4.6 million in 2024, then soared by 1331.49% to $65.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Net Cash Flow are $65.4 million (Q4 2025), -$149.0 million (Q3 2025), and $200.1 million (Q2 2025).